Immunotherapy clinical trial assesses opportunity to prevent lung cancer development, recurrence
An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the disease from developing in people with pre-cancerous lung nodules.
The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology.
How...
Metastatic cells, mechanisms of drug resistance identified for triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Combination therapy key in two studies of blood cancers likely to relapse
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
Immunotherapy innovation: Moon Shots effort aims natural killer cells at cancer
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
By working closely...
Moon Shot deploys policy help, education and clinical trial innovation against tobacco use
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...
Moon Shot promotes efforts to prevent, quickly detect pancreatic cancer
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...
Mutations in tumor-adjacent tissues could reveal earliest events leading to malignancy
MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent...
Immunotherapy combination is greater than the sum of its parts
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
E-cigarettes: Unstandardized, under-regulated, under-studied – safety unknown
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
TRACTION accelerates translation of discoveries into new clinical approaches
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies...
Computer-assisted design technology complements navigation system in pioneering orthopaedic surgery
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...
APOLLO’s high-quality longitudinal samples empower cancer investigators
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Multiple studies show major lack of public knowledge about HPV vaccine and cancer prevention
Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine...
Moon Shot rises to challenge of glioblastoma
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Lung cancer targeted therapy hits common HER2 variants across cancers
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Breast, ovarian cancer trials find targeted therapies provide benefit over chemotherapy
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
Studies show early success for pre-surgical immunotherapy in liver cancer, cutaneous head and neck cancer
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
Study identifies novel therapeutic approach for head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery...
AML drug may be good for KRAS-driven pancreatic cancer, computer-aided drug discovery finds
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...
Predicting head and neck cancer treatment toxicities with machine learning
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...
Moon Shot concentrates on treating, preventing high-risk multiple myeloma
Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110...
Research finds evidence HPV vaccine is improving herd immunity
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...
Vaguely seen on images, lung nodules’ genomics outline progression to cancer
Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them that understanding...
Study finds women disproportionally absent from clinical trials leadership
Even as women have gained ground in oncology, they remain under-represented as leaders of phase III clinical trials, MD Anderson researchers...
Triple combination therapy with nivolumab is feasible for AML, MDS patients
The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...
Moon Shot confronts challenges of multiple cancers driven by HPV
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
Study defines genetic pathway for hard-to-treat form of lymphoma
A study at The University of Texas MD Anderson Cancer Center has shed information on a novel oncogenic pathway and points to the use of BET...
Moon Shot helps corner aggressive-variant prostate cancer
Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...
Blocking protein reduces fibrosis, thwarts ovarian and pancreatic cancer
Using an antibody to plug a protein secreted by fibrous tissues in tumors stifles ovarian and pancreatic cancer in mouse models by reducing...
New approach enhances PD-L1 detection to aid in immunotherapy selection
Just as a driver’s night vision improves by simply cleaning the headlights, scientists at The University of Texas MD Anderson Cancer Center...
International consortium publishes recommendations for neoadjuvant melanoma trials
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...
Long non-coding RNA implicated in triple negative breast cancer
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...
MD Anderson advances novel therapeutic antibody into AML clinical trials
Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...
Triple combination shows promise against advanced melanoma
Combining two types of drugs that, separately, have extended the lives of people with metastatic melanoma has yielded higher response rates...
V. Craig Jordan honored by Queen Elizabeth II for impact on women’s health
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been recognized for his “services to women’s health” with his appointment...
Hortobagyi honored by ASCO for his work against breast cancer
Improvements in breast cancer treatment over the past five decades have reduced the mortality rate of women with the disease by 40 percent...
Innovative combination clinical trial results revealed at ASCO
MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American...
Evolutionary selection of pancreatic cancer cells leads to chemoresistance
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
Novel oncogene hnRNPK identified for B-cell lymphomas
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
Inducible immune resistance to protect lungs earns prestigious support
Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens...
Anti-CTLA-4 immunotherapy creates new T cells while freeing them to fight
Nobel Laureate Jim Allison, Ph.D., invented immune checkpoint blockade immunotherapy by blocking the CTLA-4 protein on T cells, freeing those...
Amplifying genetic testing to better prevent hereditary cancers
Testing for BRCA1 and BRCA2 seeks to identify mutations associated with increased risk of developing certain cancers over a person’s lifetime...
Combination chemotherapy before blood stem cell transplant improves progression-free survival
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...
Shielding healthy organs from radiotherapy for pancreatic cancer
Unresectable pancreatic cancer is usually fatal because other treatments, such as radiation therapy, cannot be used. Radiation therapy causes...
Study shows early-onset colorectal cancers have distinct features
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of Texas...
Funding that makes a difference for cancer patients
Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income...
Pancreatic Cancer Moon Shot sharpens pre-surgical treatment
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...
The search for valuable cancer-related proteins
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...
Treatment advances for CLL, the most common leukemia
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
Immunotherapy before surgery for glioblastoma shows promise
Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months...
Immunotherapy advances in targeting pancreatic, prostate and kidney cancers
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...
Immunotherapy leader details ongoing expansion of cancer treatment's reach
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...
$5.1 million grant to expand cervical cancer diagnosis and prevention in Mozambique
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...
Dream Team targets T-cell lymphoma using CAR-modified cells in experimental therapy
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...
What’s next for targeting cancer DNA repair with PARP inhibitors?
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...
Expressive writing improves quality of life for breast cancer survivors
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...
Cutting-edge MRI-guided radiation therapy provides real-time view of tumors
An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they use...